国产精品天干天干,亚洲毛片在线,日韩gay小鲜肉啪啪18禁,女同Gay自慰喷水

歡迎光臨散文網(wǎng) 會員登陸 & 注冊

【熱門產(chǎn)品推介】武漢佰樂博代理:Research Grade Lucatumumab

2023-06-30 09:45 作者:AtaGenix-普健生物  | 我要投稿

武漢佰樂博代理:Research Grade Lucatumumab ?

貨號:DHD68905

產(chǎn)品鏈接:http://www.atagenix.com/product_detail-75458.html

產(chǎn)品購買聯(lián)系方式:027-65279366

產(chǎn)品介紹:Lucatumumab (HCD122)是一種全人抗CD40拮抗劑單克隆抗體,可阻斷CD40/ CD40L介導的信號通路。Lucatumumab可有效介導抗體依賴性細胞介導的細胞毒性(ADCC)和腫瘤細胞清除,可用于頑固性淋巴瘤、慢性淋巴細胞白血病(CLL)和多發(fā)性骨髓瘤研究。

通用名Lucatumumab

純度>95% by SDS-PAGE.

濃度1mg/ml

Formulationicon0.01M PBS, pH 7.4.

內(nèi)毒素Please contact with the lab for this information.

別名CHIR-12, 12, HCD122

靶點;物種Human CD40/TNFRSF5

種類Homo sapiens

受體鑒定IgG1-kappa

CAS: 903512-50-5

存儲條件Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻:

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. PMID: 22475052

Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. PMID: 24219359

Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinations. PMID: 26758550

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. PMID: 22861192

Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling. PMID: 31404613

Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. PMID: 24555495

Emerging immune targets for the treatment of multiple myeloma. PMID: 29421983

Emerging antibodies for the treatment of multiple myeloma. PMID: 27195659

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). PMID: 29572070

Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. PMID: 25249370

Interfering with CD40 ligation: a sensitive matter in chronic lymphocytic leukemia. PMID: 22563816

?


【熱門產(chǎn)品推介】武漢佰樂博代理:Research Grade Lucatumumab的評論 (共 條)

分享到微博請遵守國家法律
安平县| 普格县| 泸水县| 崇仁县| 正镶白旗| 天祝| 于田县| 龙川县| 夏河县| 民和| 绥芬河市| 荣成市| 来凤县| 双柏县| 陆川县| 本溪市| 子洲县| 化隆| 潮安县| 榆树市| 吉木乃县| 水富县| 池州市| 甘谷县| 临潭县| 常熟市| 双峰县| 玉门市| 南陵县| 志丹县| 额尔古纳市| 峨山| 大田县| 南川市| 武山县| 类乌齐县| 丰镇市| 临沭县| 蒙山县| 濉溪县| 西平县|